SK Biopharmaceuticals’ shares successfully debut on the Kospi stock market

In the midst of growing global interest in Korea’s biotechnology industry, SK Biopharmaceuticals debuted onto the Korean stock market, Kospi, at double its initial public offering price. SK Biopharmaceuticals’ shares began trading at ₩98,000 or A$118.03 on July 2 before reaching the permissible daily limit of 30% (₩127,000 or A$152.00) within a couple of hours.

SK Biopharmaceuticals’ success will support their ongoing research and development of drugs to treat epilepsy, schizophrenia, attention deficit hyperactivity disorder and rare neurological diseases.

Click here to read more. 

AKBC Membership

AKBC welcomes new members from both the Australian and Korean business community.

Join now

What’s on

AKBC runs events on a regular basis to keep members informed about the latest developments in Australia-Korea trade and investment.

See events

AKBC Newsletter

AKBC issues a monthly newsletter about the latest trends and developments in the Australia-Korea relationship. Sign up to our free e-newsletter by entering your email below.

Australia Korea Business Council
PO Box 24430
Melbourne, Vic 3001 Australia
Liz Griffin – Executive Director

The Australia-Korea Business Council is the leading national body committed to strengthening the Australia-Korea economic relationship.